- Home
- WKSP vs GLTO Comparison
WKSP vs GLTO Comparison
Compare WKSP & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKSP
- GLTO
- Stock Information
- Founded
- WKSP 2003
- GLTO 2011
- Country
- WKSP United States
- GLTO Denmark
- Employees
- WKSP N/A
- GLTO N/A
- Industry
- WKSP Auto Parts:O.E.M.
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- WKSP Consumer Discretionary
- GLTO Health Care
- Exchange
- WKSP Nasdaq
- GLTO Nasdaq
- Market Cap
- WKSP 21.9M
- GLTO 23.7M
- IPO Year
- WKSP N/A
- GLTO 2020
- Fundamental
- Price
- WKSP $2.77
- GLTO $5.71
- Analyst Decision
- WKSP Strong Buy
- GLTO
- Analyst Count
- WKSP 3
- GLTO 0
- Target Price
- WKSP $12.83
- GLTO N/A
- AVG Volume (30 Days)
- WKSP 311.7K
- GLTO 767.1K
- Earning Date
- WKSP 11-13-2025
- GLTO 11-04-2025
- Dividend Yield
- WKSP N/A
- GLTO N/A
- EPS Growth
- WKSP N/A
- GLTO N/A
- EPS
- WKSP N/A
- GLTO N/A
- Revenue
- WKSP $12,395,166.00
- GLTO N/A
- Revenue This Year
- WKSP $159.83
- GLTO N/A
- Revenue Next Year
- WKSP $84.48
- GLTO N/A
- P/E Ratio
- WKSP N/A
- GLTO N/A
- Revenue Growth
- WKSP 232.13
- GLTO N/A
- 52 Week Low
- WKSP $2.44
- GLTO $2.01
- 52 Week High
- WKSP $12.00
- GLTO $31.70
- Technical
- Relative Strength Index (RSI)
- WKSP 38.77
- GLTO 42.02
- Support Level
- WKSP $3.00
- GLTO $7.02
- Resistance Level
- WKSP $3.44
- GLTO $7.64
- Average True Range (ATR)
- WKSP 0.21
- GLTO 0.58
- MACD
- WKSP -0.05
- GLTO -0.55
- Stochastic Oscillator
- WKSP 0.00
- GLTO 0.00
About WKSP Worksport Ltd.
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers. It operates in two reporting segments for financial reporting purposes: Hard Tonneau Covers and Soft Tonneau Covers. Geographically, the company operates in Canada, United States and Other Countries.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.